Earnings Ahead

GOSS - Gossamer Bio, Inc

1.33 -0.05 -3.62

Gossamer Bio, Inc

Gossamer Bio, Inc

About

Profile

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.


Headquarters

California, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

GOSS



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Gossamer Bio undergoes strategic restructuring; 25% of staff laid off
  • Gossamer Bio GAAP EPS of -$0.52 beats by $0.02
  • Gossamer ends development of phase 1 lymphoma candidate after clinical hold
  • Gossamer Bio GAAP EPS of -$0.59 beats by $0.03
  • Gossamer downgraded at Raymond James after Merck data for PAH candidate
  • Gossamer initiated Neutral at Guggenheim citing challenges for PAH therapy
  • CTRM, NIU and GOTU among premarket losers
  • Gossamer Bio downgraded to Equal Weight at Barclays after PAH readout
  • Gossamer Bio selloff is an overreaction - Piper Sandler
  • Gossamer sheds 63% even as PAH candidate reaches main goal in Phase 2 trial
  • Catalyst watch: Eyes on Zoom Video earnings, Best Buy call, Mobileye ratings, DWAC vote and Polestar's reveal
  • Gossamer Bio GAAP EPS of -$0.65 misses by $0.01
  • Wedbush expects positive phase 2 data readout from Gossamer Bio, starts with outperform
  • Gossamer Bio GAAP EPS of -$0.74 misses by $0.04
  • These stocks are on the most crowded shorts list - watch out above
  • Gossamer Bio to raise $120M in a private equity placement
  • Gossamer Bio GAAP EPS of -$0.76 in-line
  • Gossamer stock slumps 12% as HC Wainwright/Barclays cut price target following phase 2 trial miss
  • Gossamer Bio says mid-stage trial for ulcerative colitis therapy did not meet main goals
  • Gossamer Bio stock rises 8% as UBS initiates with Buy on 'near-term upside'

Earnings History

Date EPS / Forecast Revenue / Forecast
November 8, 2021 -0.8 / -0.785 - / -
August 9, 2021 -0.8 / -0.758 - / -
May 18, 2021 - / -0.7675 - / -
May 6, 2021 -0.78 / -0.756 - / -
February 25, 2021 -0.88 / -0.79 - / -
November 10, 2020 -0.8 / -0.8533 - / -
August 11, 2020 -1 / -0.86 - / -
May 19, 2020 - / -0.82 - / -
March 24, 2020 -0.89 / -0.86 - / -
November 12, 2019 -0.8 / -0.7 - / -
August 8, 2019 -0.74 / -0.56 - / -
May 14, 2019 -0.41 / - - / -
March 22, 2019 -4.92 / -1 - / -
Date Price Open High Low Vol Change ER
Oct 9, 2023 0.65 0.66
0.67
0.62
1.5M -2.99%
Oct 6, 2023 0.67 0.68
0.7
0.66
1.0M -1.47%
Oct 5, 2023 0.68 0.69
0.7
0.66
1.3M -2.86%
Oct 4, 2023 0.7 0.72
0.73
0.68
2.1M -4.11%
Oct 3, 2023 0.73 0.76
0.77
0.7
1.3M -5.19%
 
Oct 2, 2023 0.77 0.81
0.81
0.76
960K -7.23%
Sep 29, 2023 0.83 0.77
0.85
0.76
1.1M 6.41%
Sep 28, 2023 0.78 0.79
0.8
0.76
845K -1.27%
Sep 27, 2023 0.79 0.78
0.81
0.77
1.2M 0%
Sep 26, 2023 0.79 0.77
0.81
0.76
946K 1.28%
Sep 25, 2023 0.78 0.79
0.8
0.76
1.6M -2.5%
Sep 22, 2023 0.8 0.85
0.85
0.78
1.9M -3.61%
Sep 21, 2023 0.83 0.87
0.87
0.82
1.3M -6.74%
Sep 20, 2023 0.89 0.91
0.95
0.88
1.2M -4.3%
Sep 19, 2023 0.93 0.93
0.95
0.89
3.3M -1.06%
Sep 18, 2023 0.94 0.88
0.96
0.87
4.5M 2.17%
Sep 15, 2023 0.92 0.86
0.93
0.84
9.3M 4.55%
Sep 14, 2023 0.88 0.92
0.96
0.85
4.3M -5.38%
Sep 13, 2023 0.93 0.95
0.99
0.91
3.6M -2.11%
Sep 12, 2023 0.95 0.98
1.01
0.93
1.4M -2.06%
Sep 11, 2023 0.97 0.97
1.02
0.95
1.5M -2.02%
Sep 8, 2023 0.99 0.98
1.02
0.93
2.4M 2.06%
Sep 7, 2023 0.97 1.03
1.03
0.95
3.4M -4.9%
Sep 6, 2023 1.02 1.03
1.04
1.01
1.2M 0%
Sep 5, 2023 1.02 1.06
1.09
1.01
1.5M -2.86%
Sep 1, 2023 1.05 1.06
1.13
1.02
2.6M 0.96%
Aug 31, 2023 1.04 1.08
1.13
1.04
2.2M -2.8%
Aug 30, 2023 1.07 1.07
1.09
1.04
818K 0%
Aug 29, 2023 1.07 1.01
1.07
1
3.0M 7%
Aug 28, 2023 1 1.02
1.08
1
739K -1.96%
Aug 25, 2023 1.02 1.04
1.04
0.98
641K -0.97%
Aug 24, 2023 1.03 1.03
1.05
1
763K -1.9%
Aug 23, 2023 1.05 1.05
1.08
1.03
638K 1.94%
Aug 22, 2023 1.03 1.06
1.08
1
1.4M -1.9%
Aug 21, 2023 1.05 1.01
1.08
1
1.2M 3.96%
Aug 18, 2023 1.01 0.99
1.06
0.98
1.9M -0.98%
Aug 17, 2023 1.02 1.08
1.08
0.99
2.6M -5.56%
Aug 16, 2023 1.08 1.12
1.14
1.06
1.9M -5.26%
Aug 15, 2023 1.14 1.15
1.18
1.12
584K -2.56%
Aug 14, 2023 1.17 1.16
1.17
1.09
2.0M 0%
Aug 11, 2023 1.17 1.19
1.21
1.16
1.9M -2.5%
Aug 10, 2023 1.2 1.23
1.26
1.19
1.5M 0%
Aug 9, 2023 1.2 1.26
1.29
1.18
1.8M -1.64%
Aug 8, 2023 1.22 1.29
1.29
1.21
1.2M -5.43%
Aug 7, 2023 1.29 1.33
1.34
1.23
935K 1.57%
Aug 4, 2023 1.27 1.37
1.39
1.26
990K -6.62%
Aug 3, 2023 1.36 1.37
1.43
1.35
1.9M -2.16%
Aug 2, 2023 1.39 1.36
1.42
1.35
1.7M 0%
Aug 1, 2023 1.39 1.33
1.44
1.3
2.1M 2.96%
Jul 31, 2023 1.35 1.29
1.36
1.26
1.8M 5.47%
Jul 28, 2023 1.28 1.23
1.29
1.16
2.1M 5.79%
Jul 27, 2023 1.21 1.24
1.25
1.15
4.3M -3.97%
Jul 26, 2023 1.26 1.26
1.33
1.25
1.6M 0.80%
Jul 25, 2023 1.25 1.33
1.33
1.24
2.9M -6.72%
Jul 24, 2023 1.34 1.36
1.44
1.26
3.3M -0.74%
Jul 21, 2023 1.35 1.3
1.43
1.18
8.0M 8.87%
Jul 20, 2023 1.24 1.76
1.88
1.23
17.4M -31.87%
Jul 19, 2023 1.82 1.63
1.84
1.63
1.9M 13.75%
Jul 18, 2023 1.6 1.6
1.65
1.55
801K 4.58%
Jul 17, 2023 1.53 1.54
1.56
1.45
635K 0%